Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

A Retrospective Analysis of Co-morbidities in Stroke Patients with COVID
Cerebrovascular Disease and Interventional Neurology
P14 - Poster Session 14 (11:45 AM-12:45 PM)

Given the protean sequelae of COVID-19 and its emerging interplay on chronic disease states, the effects of well-established stroke risk factors must be analyzed in this context.

To analyze the effects of co-morbidities established as stroke risk factors in the setting of coronavirus disease 2019 (COVID-19).

We conducted a retrospective analysis on 29 patients who presented with acute stroke and were found to be COVID-19 positive from 3/2020 through 8/2021. Information was collected on demographic variables, medical history, and pertinent clinical parameters. Stroke outcomes were assessed via the following: binarized modified Rankin scale score (mRSS) on discharge (4-6: poor outcome vs 0-3: good outcome [ref]), and whether mortality resulted. A series of logistic regression models adjusted for age, gender, body mass index, presence of diabetes mellitus (DM), presence of hyperlipidemia, prior history of coronary artery disease and/or cerebrovascular disease, and mean arterial pressure at admission were run to assess the association of these parameters with stroke outcomes in a cohort of COVID-19 positive stroke patients. All analyses were conducted using SAS Studio OnDemand for Academics (SAS Institute Inc., Cary, NC).

Among 29 COVID-19 patients (mean age 63.6 + 13.4 years, 65.5% males), tested clinical parameters were not shown to be significantly associated with stroke outcomes across a series of logistic regression models. Regarding mortality, presence of DM showed 5.89 times the odds of mortality (OR: 5.89; 95% CI: 0.67, 52.47; p-value: 0.11). When assessing for binarized mRSS at discharge, presence of DM showed 2.97 times the odds of a poor outcome (OR: 2.97, 95% CI: 0.27, 32.58; p-value: 0.37).

Analysis via adjusted logistic regression models revealed a statistically insignificant positive association between DM and both outcomes: worse mRSS and mortality. Further research is needed with larger patient cohorts and employing matched controls without COVID.

Mohammad Abdurrehman Sheikh, MBBS (LSU Health Shreveport)
Dr. Sheikh has nothing to disclose.
Junaid Ansari, MD (LSU Health Shreveport) Dr. Ansari has nothing to disclose.
Omar Elsekaily, MBBS (LSU shreveport) Dr. Elsekaily has nothing to disclose.
Muhammad Ayub, MD (Louisiana State University, Shreveport) Dr. Ayub has nothing to disclose.
Rachel Elizabeth Triay, MD (Case Western / University Hospitals Cleveland) Dr. Triay has nothing to disclose.
Alexis Angelette, MD (New York Presbyterian) Miss Angelette has nothing to disclose.
Alexandra Gaudet Ms. Gaudet has nothing to disclose.
Roger E. Kelley, Jr., MD, FAAN (LSU Health Sciences Center) Dr. Kelley has nothing to disclose.